This year’s theme for Rheumatic Disease Awareness Month focuses on self-management, aiming to provide tools and tips to empower patients, boost awareness about the importance of self-management and, ultimately, improve patient outcomes.
Search results for: biosimilars
Draft FDA Guidance No Longer Requires Biosimilar Switching Studies
The updated draft guidance, released in June, would accept an assessment of why data provided meet the switching standard to demonstrate interchangeability of biosimilars
AWIR & ACR: Building a Strong Future Rheumatology Community
The ACR was fortunate to participate in the Association for Women in Rheumatology’s 2024 Annual Meeting in Orlando. As this relationship grows every year, the AWIR and ACR are working together to build a sustainable and inclusive rheumatology community for the future.
Meet the ACR’s Advocacy Team
It’s an election year, and ACR staff are excited about the possibility of moving key initiatives, such as Medicare reimbursement, across the finish line. But they need members’ help to do so.
ACR Delegation to Lead Several Resolutions at June AMA House of Delegates Meeting
The ACR will lead five other specialty societies on a resolution supporting pediatric specialty care and will co-lead resolutions addressing Medicare Advantage Part B drug coverage, white bagging mandates, state prescription drug affordability boards and impacts of alternative funding programs on access to care.
FDA Proposal for Biosimilar Use in 2025 Budget
A proposal for biosimilar use in the 2025 budget would allow substitution of any biosimilar for its reference product without an interchangeable designation. The hope is to increase biosimilar uptake, with the subsequent potential to increase product “competition, access and affordability.”1 In the 2025 budget proposal, the Biden administration noted that the legal distinction between…
Gwenesta B. Melton, MD, Appointed New Chair of Affiliate Society Council
Gwenesta B. Melton, MD, wears many hats as a rheumatologist, teacher and champion for advocacy and collaboration. She has been involved with the ASC for more than a decade.
Updates from the ACR Insurance Subcommittee
The Insurance Subcommittee is working to address coverage and reimbursement challenges facing rheumatology practices, including issues related to biosimilar use, in-office treatments and the new G2211 code.
The Biosimilar Economic Conundrum: Where We Stand
Reimbursement has fallen below acquisition price for some biosimilar versions of infliximab, forcing practices and patients to make difficult decisions. The ACR is working to change this.
Advancing the Work of CORC: Q&A with New Chair Chris Phillips, MD
New Committee on Rheumatologic Care (CORC) Chair Chris Phillips, MD, talks about his past work with the ACR, his experience as a private practice rheumatologist and his plans to lead CORC in addressing practitioner pain points and supporting the business side of rheumatology practice.
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 32
- Next Page »